• NF 340: P2Y11 Antagonist for Advanced GPCR Pathway Research

  2026-04-30

  NF 340 enables precise modulation of P2Y11-mediated signaling, empowering researchers to dissect complex GPCR pathways in cancer and immunology. This APExBIO reagent stands out for its selectivity and proven impact on cell migration and invasion assays, as demonstrated in breast cancer research.

• Gamma-linolenic Acid (GLA): Mechanisms, Evidence, and Resear

  2026-04-30

  Gamma-linolenic acid (GLA) is an omega-6 polyunsaturated fatty acid with validated anti-inflammatory and cytoprotective properties. GLA acts as a weak Leukotriene B4 receptor antagonist and is supported by robust in vitro and in vivo data for use in anti-inflammatory research and clinical models.

• Intracellular Aminopeptidase Inhibition in Myeloma: Mechanis

  2026-04-29

  The referenced study elucidates that aminopeptidase inhibitors bestatin and actinonin suppress myeloma cell proliferation primarily via intracellular mechanisms, rather than by targeting cell surface aminopeptidases. This finding redefines how intracellular drug accumulation and efflux modulation, including the use of L-type calcium channel blockers like verapamil, can influence anti-cancer strategies.

• URB597 (KDS-4103): Applied FAAH Inhibition in Neuroplasticit

  2026-04-29

  URB597 (KDS-4103) from APExBIO empowers researchers with precise, selective FAAH inhibition, unlocking robust endocannabinoid modulation for neuroplasticity and neuroinflammation studies. This article details advanced workflows, troubleshooting strategies, and translational insights inspired by recent multidimensional pain research.

• Gamma-Linolenic Acid (GLA): Translational Leverage in Anti-I

  2026-04-28

  This thought-leadership article explores the scientific and strategic value of gamma-linolenic acid (GLA) in translational research, with mechanistic insights, evidence-backed protocol guidance, and outlook on clinical and workflow impact, specifically highlighting APExBIO’s research-grade GLA.

• Morning Training Drives Enhanced Endurance Adaptations in Mi

  2026-04-28

  This study demonstrates that the timing of endurance exercise significantly influences physiological adaptation in mice, with morning-trained animals showing more efficient improvements than those trained in the afternoon. The results highlight the importance of exercise timing as a modifiable variable in preclinical research on endurance and metabolic adaptation.

• LGK-974 in Wnt Pathway Inhibition: Mechanistic and Translati

  2026-04-27

  This thought-leadership article explores the mechanistic underpinnings and translational potential of LGK-974, a potent and specific PORCN inhibitor, in the context of Wnt signaling modulation for cancer research. By bridging recent developmental biology insights with preclinical oncology evidence, we provide actionable guidance for translational researchers seeking to leverage LGK-974 in Wnt-driven cancer models, particularly those involving pancreatic cancer with RNF43 mutation. The discussion critically evaluates experimental protocols, competitive landscape, and future perspectives, with APExBIO's LGK-974 positioned as a key research tool.

• Protease Inhibitor Cocktail (MS-SAFE, 50X in DMSO): Practica

  2026-04-27

  The Protease Inhibitor Cocktail (MS-SAFE, 50X in DMSO) is engineered to prevent protein degradation during extraction, particularly for mass spectrometry (MS) and biochemical workflows where AEBSF must be avoided. It should not be used for experiments requiring metalloproteinase inhibition unless supplemented with EDTA.

• U-73122: Precision Phospholipase C Inhibition in Cell Signal

  2026-04-26

  U-73122, a potent phospholipase C inhibitor, empowers researchers to dissect PLC-β2-mediated signaling in inflammation and cancer metastasis models. With robust data-driven protocols and troubleshooting strategies, U-73122 enables precise, reproducible modulation of calcium flux and chemotaxis in complex cellular assays.

• Myriocin: Translating Sphingolipid Insights to Oncology & Be

  2026-04-25

  This thought-leadership article explores the mechanistic role of myriocin as a selective serine palmitoyltransferase inhibitor in sphingolipid metabolism research, focusing on its profound implications for cancer research and cell cycle regulation. Integrating recent network pharmacology findings and translational workflows, the discussion provides strategic guidance for researchers aiming to leverage myriocin’s unique properties for innovative experimental design and clinical translation. Key protocol parameters, comparative landscape insights, and a forward-looking outlook ground the article as an evidence-driven resource for the translational science community.

• ACSL1 Modulates Mitophagy to Attenuate Pulmonary Fibrosis

  2026-04-24

  This study demonstrates that ACSL1 overexpression reduces mitochondrial damage and activates PINK1/Parkin-mediated mitophagy, offering a novel mechanism for alleviating pulmonary fibrosis in bleomycin-induced models. The findings suggest that targeting mitochondrial quality control could provide new therapeutic strategies for chronic fibrotic lung disease.

• Brain-to-Spinal Circuits Regulate Mechanical Allodynia Later

  2026-04-24

  Huo et al. (2023) identified a specific brain-to-spinal neural circuit that determines both the laterality (unilateral vs. bilateral) and duration of mechanical allodynia in mice. Their findings clarify how contralateral descending pathways modulate pain hypersensitivity, offering mechanistic insights relevant to preclinical models of chronic pain.

• Wnt-EGFR Crosstalk Regulates DNA Damage Response in Drosophi

  2026-04-23

  This study elucidates how canonical Wnt signaling, via EGFR pathway activation, confers resistance to apoptosis following DNA double-strand breaks in the Drosophila wing imaginal disc. The findings provide mechanistic insight into the interplay between developmental signals and the DNA damage response, with implications for understanding tissue-specific susceptibility to genotoxic stress and chemoresistance.

• NU7441 (KU-57788): Selective DNA-PK Inhibitor for DNA Repair

  2026-04-23

  NU7441 (KU-57788) is a potent, ATP-competitive DNA-PK inhibitor with high selectivity and nanomolar efficacy. It enables precise study of DNA repair and cell cycle regulation in oncology research. Its benchmarked specificity and robust in vitro/in vivo profiles make it a cornerstone for mechanistic and translational workflows.

• Balancing Self-Renewal and Differentiation in Human Intestin

  2026-04-22

  This article reviews a recent study that establishes an optimized human intestinal organoid system capable of balancing stem cell self-renewal with differentiation, without the need for artificial spatial gradients. The findings enable scalable, diverse organoid cultures and provide a foundation for advanced applications in disease modeling and drug testing.

15461 records 1/1031 page Next 12345 下5页 Last page